Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | DTYMK | P23919 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HCAR3 | P49019 | 10/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851121 | 1.00 | CASP6 (0.72) | CASP6TSHRDTYMKLMNAHCAR3 | |
| SCHEMBL29249351 | 0.98 | CASP6 (0.70) | CASP6TSHRDTYMKLMNAHCAR3 | |
| SCHEMBL30931540 | 0.87 | DTYMK (0.58) | CASP6TSHRDTYMKLMNAHCAR3 | |
| SCHEMBL2711636 | 0.87 | DTYMK (0.58) | CASP6TSHRDTYMKLMNAHCAR3 | |
| SCHEMBL30810715 | 0.85 | CASP6 (0.72) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL842661 | 0.85 | CASP6 (0.72) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL145092 | 0.85 | CASP6 (0.72) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL27680384 | 0.84 | SRD5A2 (0.67) | CASP6TSHRLMNAHCAR3POLB | |
| SCHEMBL9199250 | 0.84 | MAPK1 (0.68) | CASP6TSHRDTYMKPOLBTDP1 | |
| SCHEMBL504055 | 0.84 | CASP6 (1.00) | CASP6TSHRLMNAHCAR3APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344743-B | High-viscosity modified asphalt and preparation method thereof | 南京航空航天大学 | 2024-11-26 | — | — | CN | claimed |
| CN-118344743-A | High-viscosity modified asphalt and preparation method thereof | 南京航空航天大学 | 2024-07-16 | — | — | CN | claimed |
| CN-118324640-A | Method for recycling 4-nitroisophthalic acid by using mother liquor of 5-nitroisophthalic acid production | 江西大宇医药股份有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117659906-A | Packaging adhesive film composition, packaging adhesive film and application | 福斯特(滁州)新材料有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | GUILFORD PHARMACEUTICALS INC. | 2005-04-14 | — | — | US | claimed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| WO-2003057154-A2 | NAALADASE INHIBITORS FOR TREATING HUNTINGTON'S DISEASE | GUILDFORD PHARMACEUTICALS INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-20030083505-A1 | Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors | EISAI INC. | 2003-05-01 | — | — | US | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| US-6452044-B2 | NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-09-17 | — | — | US | claimed |
| US-20020019430-A1 | Nervous system and psychological disorders | EISAI INC. | 2002-02-14 | — | — | US | claimed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2001091738-A2 | NAALADASE INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| CN-119530999-B | Method for preparing polyetherimide fiber by oxidation method | 东营市海科瑞林化工有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-4122119-A | Process for the production of unsaturated ketones | KURARAY CO., LTD. (JP) | 1978-10-24 | — | — | US | disclosed |
| US-4002664-A | Manufacture of dimethylaminobenzenecarboxylic acid esters | BASF AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | CASP6 2689/4885TSHR 4825/4885DTYMK 2057/4885 |
| US-20030083505-A1 | Spinal cord injury, demyelinating diseases, Parkinson's disease, Amyotrophic Lateral Sclerosis, alcohol, nicotine, cocaine dependence, neuropathy, pain and schizophrenia; antiischemic, - carcinogenic agents; NAALADase inhibitors | NGF, GAP43, ACHE | CASP6 1862/4885TSHR 4435/4885DTYMK 3251/4885 |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | HTT, GAA, ADA | CASP6 1840/4885TSHR 3380/4885DTYMK 344/4885 |
| US-20020019430-A1 | Nervous system and psychological disorders | GLUL, DDC, DNPEP | CASP6 855/4885TSHR 4664/4885DTYMK 1992/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | CASP6 4206/4885TSHR 4169/4885DTYMK 670/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | CASP6 2769/4885TSHR 3404/4885DTYMK 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.